These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 11406730

  • 1. Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
    Mukherjee D, Chew DP, Robbins M, Yadav JS, Raymond RE, Moliterno DJ.
    J Thromb Thrombolysis; 2001 Apr; 11(2):151-4. PubMed ID: 11406730
    [Abstract] [Full Text] [Related]

  • 2. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [Abstract] [Full Text] [Related]

  • 3. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ, TENACITY Steering Committee and Investigators.
    Catheter Cardiovasc Interv; 2011 Jun 01; 77(7):1001-9. PubMed ID: 21598351
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
    Konopka A, Spychalska J, Sitkiewicz D, Zdebska E, Pilichowska I, Piotrowski W, Stepińska J.
    Am J Cardiovasc Drugs; 2007 Jun 01; 7(6):433-9. PubMed ID: 18076210
    [Abstract] [Full Text] [Related]

  • 7. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
    Pinkau T, Ndrepepa G, Kastrati A, Mann JF, Schulz S, Mehilli J, Schömig A.
    Cardiology; 2008 Jun 01; 111(4):247-53. PubMed ID: 18434733
    [Abstract] [Full Text] [Related]

  • 8. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
    Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ.
    Circulation; 2004 Aug 24; 110(8):994-8. PubMed ID: 15302778
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
    Topol EJ.
    Am J Cardiol; 1998 Oct 22; 82(8B):63P-68P. PubMed ID: 9809894
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
    Dangas G, Badimon JJ, Coller BS, Fallon JT, Sharma SK, Hayes RM, Meraj P, Ambrose JA, Marmur JD.
    Arterioscler Thromb Vasc Biol; 1998 Aug 22; 18(8):1342-9. PubMed ID: 9714143
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
    Assali AR, Salloum J, Sdringola S, Moustapha A, Ghani M, Hale S, Schroth G, Fujise K, Anderson HV, Smalling RW, Rosales OR.
    Am J Cardiol; 2001 Oct 15; 88(8):884-6, A6. PubMed ID: 11676953
    [No Abstract] [Full Text] [Related]

  • 16. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A, Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators.
    N Engl J Med; 2004 Jan 15; 350(3):232-8. PubMed ID: 14724302
    [Abstract] [Full Text] [Related]

  • 17. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
    Claeys MJ, Van der Planken MG, Bosmans JM, Michiels JJ, Vertessen F, Van Der Goten P, Wuyts FL, Vrints CJ.
    Eur Heart J; 2005 Mar 15; 26(6):567-75. PubMed ID: 15618034
    [Abstract] [Full Text] [Related]

  • 18. [New antiaggregants and their importance for the practitioner].
    Tsakiris DA.
    Ther Umsch; 2003 Jan 15; 60(1):24-6. PubMed ID: 12638474
    [Abstract] [Full Text] [Related]

  • 19. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Theroux P, NICE-3 Investigators.
    Am Heart J; 2003 Oct 15; 146(4):628-34. PubMed ID: 14564315
    [Abstract] [Full Text] [Related]

  • 20. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T, Boersma E, Ruzyllo W, Widimsky P, Ohman EM, Armstrong PW, Wallentin L, Simoons ML, GUSTO IV-ACS Investigators.
    Am Heart J; 2004 May 15; 147(5):865-73. PubMed ID: 15131544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.